Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 3
2020 1
2021 4
2022 9
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Amyotrophic lateral sclerosis: a clinical review.
Masrori P, Van Damme P. Masrori P, et al. Eur J Neurol. 2020 Oct;27(10):1918-1929. doi: 10.1111/ene.14393. Epub 2020 Jul 7. Eur J Neurol. 2020. PMID: 32526057 Free PMC article. Review.
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Miller TM, et al. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. N Engl J Med. 2022. PMID: 36129998 Free article. Clinical Trial.
The sense of antisense therapies in ALS.
Van Daele SH, Masrori P, Van Damme P, Van Den Bosch L. Van Daele SH, et al. Among authors: masrori p. Trends Mol Med. 2024 Mar;30(3):252-262. doi: 10.1016/j.molmed.2023.12.003. Epub 2024 Jan 11. Trends Mol Med. 2024. PMID: 38216448 Free article. Review.
FUS-ALS hiPSC-derived astrocytes impair human motor units through both gain-of-toxicity and loss-of-support mechanisms.
Stoklund Dittlau K, Terrie L, Baatsen P, Kerstens A, De Swert L, Janky R, Corthout N, Masrori P, Van Damme P, Hyttel P, Meyer M, Thorrez L, Freude K, Van Den Bosch L. Stoklund Dittlau K, et al. Among authors: masrori p. Mol Neurodegener. 2023 Jan 18;18(1):5. doi: 10.1186/s13024-022-00591-3. Mol Neurodegener. 2023. PMID: 36653804 Free PMC article.
CRISPR/Cas9 screen in human iPSC-derived cortical neurons identifies NEK6 as a novel disease modifier of C9orf72 poly(PR) toxicity.
Guo W, Wang H, Kumar Tharkeshwar A, Couthouis J, Braems E, Masrori P, Van Schoor E, Fan Y, Ahuja K, Moisse M, Jacquemyn M, Furtado Madeiro da Costa R, Gajjar M, Balusu S, Tricot T, Fumagalli L, Hersmus N, Janky R, Impens F, Vanden Berghe P, Ho R, Thal DR, Vandenberghe R, Hegde ML, Chandran S, De Strooper B, Daelemans D, Van Damme P, Van Den Bosch L, Verfaillie C. Guo W, et al. Among authors: masrori p. Alzheimers Dement. 2023 Apr;19(4):1245-1259. doi: 10.1002/alz.12760. Epub 2022 Aug 22. Alzheimers Dement. 2023. PMID: 35993441 Free PMC article.
A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial.
Lombardo FL, Spila Alegiani S, Mayer F, Cipriani M, Lo Giudice M, Ludolph AC, McDermott CJ, Corcia P, Van Damme P, Van den Berg LH, Hardiman O, Nicolini G, Vanacore N, Dickie B, Albanese A, Puopolo M; TUDCA-ALS Study Group. Lombardo FL, et al. Trials. 2023 Dec 5;24(1):792. doi: 10.1186/s13063-023-07638-w. Trials. 2023. PMID: 38053196 Free PMC article. Clinical Trial.
22 results